CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

Phase 3

Active, not recruiting

Conditions: Eosinophilic Gastroenteritis

Interventions: Drug: Placebo
Drug: CC-93538

First Posted Date: 2022-01-31

Last Posted Date: 2025-05-04

Lead Sponsor: Celgene

Target Recruit Count: 48

Registration Number: NCT05214768

Locations: 🇯🇵
Local Institution - 002, Osaka, Japan
🇯🇵
Local Institution - 022, Himeji-shi, Hyogo, Japan
🇯🇵
Local Institution - 009, Nishinomiya, Hyogo, Japan

and more 22 locations

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

Phase 1

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Cendakimab
Drug: CYP substrates

First Posted Date: 2022-01-03

Last Posted Date: 2024-12-20

Lead Sponsor: Celgene

Target Recruit Count: 16

Registration Number: NCT05175352

Locations: 🇺🇸
Local Institution - 021, Plantation, Florida, United States
🇺🇸
Local Institution - 012, Columbus, Ohio, United States
🇺🇸
Local Institution - 001, Los Angeles, California, United States

and more 9 locations

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Other: Placebo
Drug: CC-97489

First Posted Date: 2021-10-29

Last Posted Date: 2023-12-14

Lead Sponsor: Celgene

Target Recruit Count: 84

Registration Number: NCT05099822

Locations: 🇧🇪
Local Institution - 001, Leuven, Vlaams Brabant, Belgium

Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-97489
Drug: [18F]T-401
Drug: [11C]MK-3168

First Posted Date: 2021-10-04

Last Posted Date: 2024-02-16

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT05065541

Locations: 🇧🇪
Local Institution - 001, Leuven, Vlaams Brabant, Belgium

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Phase 3

Completed

Conditions: Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting

Interventions: Biological: Tetanus, diphtheria, and acellular pertussis vaccine
Biological: Pneumococcal polysaccharide vaccine
Biological: Seasonal influenza vaccine

First Posted Date: 2021-08-31

Last Posted Date: 2025-02-11

Lead Sponsor: Celgene

Target Recruit Count: 63

Registration Number: NCT05028634

Locations: 🇺🇸
Hartford Healthcare CT, Southington, Connecticut, United States
🇺🇸
Shapiro Center for MS at the Minneapolis Clinic of Neurology, Minneapolis, Minnesota, United States
🇺🇸
South Shore Neurology Associates, Inc, Patchogue, New York, United States

and more 30 locations

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Phase 3

Active, not recruiting

Conditions: Eosinophilic Esophagitis

Interventions: Drug: CC-93538

First Posted Date: 2021-08-05

Last Posted Date: 2024-11-27

Lead Sponsor: Celgene

Target Recruit Count: 259

Registration Number: NCT04991935

Locations: 🇺🇸
Local Institution - 082, Phoenix, Arizona, United States
🇺🇸
Local Institution - 041, Scottsdale, Arizona, United States
🇺🇸
Local Institution - 029, Tucson, Arizona, United States

and more 164 locations

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Terminated

Conditions: Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Lymphoma, Large B-Cell, Diffuse

First Posted Date: 2021-07-29

Last Posted Date: 2025-03-11

Lead Sponsor: Celgene

Target Recruit Count: 36

Registration Number: NCT04982471

Locations: 🇺🇸
Local Institution - 133, Topeka, Kansas, United States
🇺🇸
Local Institution - 139, Chevy Chase, Maryland, United States
🇺🇸
Local Institution - 141, Howell, New Jersey, United States

and more 50 locations

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Other: Placebo
Drug: Phenelzine
Drug: Rasigiline
Drug: Ozanimod

First Posted Date: 2021-07-27

Last Posted Date: 2023-08-31

Lead Sponsor: Celgene

Target Recruit Count: 128

Registration Number: NCT04978298

Locations: 🇺🇸
Local Institution - 001, Anaheim, California, United States

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Daratumumab
Drug: Bortezomib
Drug: Iberdomide

First Posted Date: 2021-07-26

Last Posted Date: 2025-05-18

Lead Sponsor: Celgene

Target Recruit Count: 864

Registration Number: NCT04975997

Locations: 🇨🇦
Local Institution - 108, Quebec, Canada
🇨🇳
Local Institution - 136, Guangzhou, China
🇨🇳
Local Institution - 128, Hangzhou City, China

and more 275 locations

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: CC-92328

First Posted Date: 2021-07-23

Last Posted Date: 2025-03-24

Lead Sponsor: Celgene

Target Recruit Count: 26

Registration Number: NCT04975399

Locations: 🇪🇸
Local Institution - 302, Pamplona, Navarra, Spain
🇨🇦
Local Institution - 204, Edmonton, Alberta, Canada
🇺🇸
Local Institution - 105, Scottsdale, Arizona, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy